With Tarik Skubal poised to sign a blockbuster contract estimated at $400 million, MLB executives are scrutinizing the Detroit Tigers ace’s medical history more closely than ever before. According to The Athletic’s Will Sammon, Ken Rosenthal, and Katie Woo, team leaders attending the general managers’ meetings expressed a strong desire for a “better understanding” of the pitcher’s physical condition. This heightened due diligence is driven by Skubal’s upcoming 30th birthday on November 20, a milestone age that often triggers deeper health assessments for high-value free agents.
Executives seek clarity on elbow history as Detroit Tigers ace approaches free agency
The primary concern stems from Skubal’s recent surgical history, which includes a 2024 procedure to remove loose bodies from his elbow, a 2022 flexor tendon surgery, and his original Tommy John surgery in 2019. Although Skubal returned to the mound just four weeks after the most recent elbow intervention, the cumulative nature of these operations has led some front offices to question long-term durability. The league’s focus on these specific medicals reflects a cautious approach to investing nearly half a billion dollars in a pitcher who has undergone multiple significant arm procedures in the last five years.
Despite the medical inquiries, Skubal’s dominance on the mound remains undeniable, making him the most sought-after pitcher in the current free agent market. Teams are balancing the risk of his arm history against the immense value of securing a top-tier starter for the next decade. As the offseason intensifies, the outcome of these medical evaluations will likely determine not only the final structure of Skubal’s contract but also which franchise ultimately secures the services of the reigning American League Cy Young Award winner.
Source: Yahoo Sports
